Cargando…

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score

Limited evidence exists on the clinical and economic burden of advanced fibrosis in patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) due to the invasiveness of liver biopsies for accurately staging liver disease. The fibrosis‐4 (FIB‐4) score allows for noninva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Stuart C., Kachru, Nandita, Parker, Emily, Korrer, Stephanie, Ozbay, A. Burak, Wong, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327220/ https://www.ncbi.nlm.nih.gov/pubmed/32626832 http://dx.doi.org/10.1002/hep4.1524

Ejemplares similares

Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
por: Wong, Robert J., et al.
Publicado: (2021)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany
por: Canbay, Ali, et al.
Publicado: (2021)

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
por: Romero-Gomez, Manuel, et al.
Publicado: (2020)

Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis
por: Wong, Robert J., et al.
Publicado: (2019)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Intragastric Balloons: An Emerging Therapy for Nonalcoholic Steatohepatitis and Fibrosis?
por: Jirapinyo, Pichamol, et al.
Publicado: (2019)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

A simple method for inducing nonalcoholic steatohepatitis with fibrosis
por: Yahaghi, Leyla, et al.
Publicado: (2019)

Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis
por: Chen, Hui, et al.
Publicado: (2022)

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
por: Younossi, Zobair M., et al.
Publicado: (2021)

Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores
por: Wu, Yonghui, et al.
Publicado: (2022)

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes
por: Younossi, Zobair M, et al.
Publicado: (2020)

Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice
por: Li, Rui, et al.
Publicado: (2018)

Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis
por: Lee, Jung Il, et al.
Publicado: (2019)

Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
por: Mueller, Jessica L, et al.
Publicado: (2015)

The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
por: Cichoż-Lach, Halina, et al.
Publicado: (2012)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
por: Mazo, Daniel FC, et al.
Publicado: (2013)

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
por: Sircana, Antonio, et al.
Publicado: (2019)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV
por: Michel, Maurice, et al.
Publicado: (2022)

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
por: Friedman, Scott L., et al.
Publicado: (2018)

Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis
por: Loureiro, Dimitri, et al.
Publicado: (2023)

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis
por: Kruger, Annie J., et al.
Publicado: (2018)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]
Publicado: (2013)

Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease
por: Hagström, Hannes, et al.
Publicado: (2018)

Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient
por: Alam, Shahinul, et al.
Publicado: (2019)

A novel diet‐induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis
por: Ejima, Chieko, et al.
Publicado: (2016)

Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis
por: Saito, Kosuke, et al.
Publicado: (2015)

DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis
por: Asada, Kiyoshi, et al.
Publicado: (2016)

Comprehensive Study of Multiple Stages Progressing to Nonalcoholic Steatohepatitis with Subsequent Fibrosis in SD Rats
por: Wang, Lulu, et al.
Publicado: (2017)

Human Liver-Derived Stem Cells Improve Fibrosis and Inflammation Associated with Nonalcoholic Steatohepatitis
por: Bruno, Stefania, et al.
Publicado: (2019)

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
por: Harrison, Stephen A., et al.
Publicado: (2019)

Effects of renalase deficiency on liver fibrosis markers in a nonalcoholic steatohepatitis mouse model
por: Tokinoya, Katsuyuki, et al.
Publicado: (2021)

Potential Hepatic Lipid Markers Associated with Nonalcoholic Steatohepatitis and Fibrosis in Morbid Obesity Patients
por: Wu, Hua-Chien, et al.
Publicado: (2023)

Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
por: Kawanaka, Miwa, et al.
Publicado: (2023)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2023)

Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis?
por: Hinz, Kaitlyn, et al.
Publicado: (2023)

Biochemical Scoring System for diagnosing Nonalcoholic Steatohepatitis
por: Noor-E-Alam, Mohammad, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g46nilrjsjbsflbjdu6tugfhp7